Evidence map›Paper›PMID 35430564›Full record

ArticleCancer genomics & proteomics

Deletion of

Yusuke Aoki, Yasunori Tome, Qinghong Han, Jun Yamamoto, Kazuyuki Hamada, Noriyuki Masaki, Yutaro Kubota, Michael Bouvet, Kotaro Nishida, Robert M Hoffman

Open access · diamondAbstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Recombinant-methioninase-producingCancer diagnosis & prognosis
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Yusuke AokiAntiCancer Inc, San Diego, CA, U.S.A.
Yasunori TomeDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan all@anticancer.com yastome@med.u-ryukyu.ac.jp.
Qinghong HanAntiCancer Inc, San Diego, CA, U.S.A.
Jun YamamotoAntiCancer Inc, San Diego, CA, U.S.A.
Kazuyuki HamadaAntiCancer Inc, San Diego, CA, U.S.A.
Noriyuki MasakiAntiCancer Inc, San Diego, CA, U.S.A.
Yutaro KubotaAntiCancer Inc, San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California San Diego, La Jolla, CA, U.S.A.
Kotaro NishidaDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Robert M HoffmanAntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com yastome@med.u-ryukyu.ac.jp.
AntiCancer (United States) · USUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMethionine addiction is a fundamental and general hallmark of cancer cells, which require exogenous methionine, despite large amounts of methionine synthesized endogenously. 5-Methylthioadenosine phosphorylase (MTAP) plays a principal role as an enzyme in the methionine-salvage pathway, which produces methionine and adenine from methylthioadenosine and is deleted in 27.5% to 37.5% of osteosarcoma patients. MATERIALS AND

methodsHuman osteosarcoma cell lines U2OS, SaOS2, MNNG/HOS (HOS) and 143B, were used. The MTAP gene was knocked out in U2OS with CRISPR/Cas9. 143B and HOS have an MTAP deletion and SaOS2 is positive for MTAP. MTAP was determined by western blotting. The four cell lines were compared for sensitivity to recombinant methioninase (rMETase).

resultsMTAP-deleted osteosarcoma cell lines MNNG/HOS and 143B were significantly more sensitive to rMETase than MTAP-positive osteosarcoma cell lines U2OS and SaOS2. In addition, MTAP knock-out U2OS cells were more sensitive to rMETase than the parental MTAP-positive U2OS cells.

conclusionThe present results demonstrated that the absence of MTAP sensitizes osteosarcoma cells to methionine restriction by rMETase, a promising clinical strategy.

Indexed as

Bone NeoplasmsMethionineOsteosarcomaPurine-Nucleoside PhosphorylaseCarbon-Sulfur LyasesCell Line, TumorHumansMethylnitronitrosoguanidineRecombinant Proteins5'-methylthioadenosine phosphorylaseCarbon-Sulfur LyasesL-methionine gamma-lyaseMethionineMethylnitronitrosoguanidinePurine-Nucleoside PhosphorylaseRecombinant ProteinsCRISPR/Cas9deletionHoffman efffectknockoutmethionine addictionmethionine restrictionMTAPOsteosarcomarecombinant methioninase

Identifiers

PMID35430564
PMCPMC9016482
OpenAlexW4224305737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.